LIVE Programme
CET Time
13:50-14:05 ESA and other growth factors Valeria Santini (Florence)
14:05-14:20 HMAs: When and how Mikkael Sekeres (Miami)
14:20-14:35 Allo Transplantation: When and how? Marie Robin (Paris)
14:35-14:50 Current treatment guidelines for CMML and rare subtypes Raphael Itzykson (Paris)
SHORT COMMUNICATION:
14:50-15:00 Circulating Small Noncoding RNAs As Novel Biomarkers Michaela Merkerova(Prague)*
in Myelodysplastic Syndromes
15:00-15:30 Panel discussion
15:30-15:40 Coffee break
SESSION VII – Current Progress in the Treatment of MDS
Chairs: Valeria Santini (Florence) & Lionel Adès (Paris)
15:40-15:45 Introduction Valeria Santini (Florence)
Lionel Ades (Paris)
15:45-16:00 Higher risk MDS: Lessons from elderly AML Lionel Adès (Paris)
A renewed role for intensive chemotherapy (CPX 351…)?
16:00-16:15 Strategies to improve HMA based therapy Pierre Fenaux (Paris)
16:15-16:30 Management of HMA failure Valeria Santini (Florence)
16:30-16:45 Novel strategies to treat cytopenia in Low Risk MDS Uwe Platzbecker (Leipzig)
SHORT COMMUNICATION:
16:45-16:55 Efficacy and Safety of Sabatolimab (MBG453) in Combination Andrew Brunner (Boston)
with Hypomethylating Agents (HMAs) in Patients with
Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic
Syndrome (HR-MDS): Updated Results from a Phase Ib Study
16:55-17:25 Panel discussion
17:25-18:25 Poster walk
Leaders for Biology: Michaela Fontenay (Paris) & Torsten Haferlach (Munich)
Leaders for Clinical: Eva Hellström-Lindberg (Stockholm) & Valeria Santini (Florence)
5